PUBLICATION

Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts

Authors
Wrobel, J.K., Najafi, S., Ayhan, S., Gatzweiler, C., Krunic, D., Ridinger, J., Milde, T., Westermann, F., Peterziel, H., Meder, B., Distel, M., Witt, O., Oehme, I.
ID
ZDB-PUB-201031-13
Date
2020
Source
Pharmaceuticals (Basel, Switzerland)   13(11): (Journal)
Registered Authors
Distel, Martin, Meder, Benjamin
Keywords
childhood cancer, histone deacetylases, precision medicine, preclinical models, small molecules, xenotransplantation
MeSH Terms
none
PubMed
33121173 Full text @ Pharmaceuticals (Basel)
Abstract
The survival rate among children with relapsed neuroblastomas continues to be poor, and thus new therapeutic approaches identified by reliable preclinical drug testing models are urgently needed. Zebrafish are a powerful vertebrate model in preclinical cancer research. Here, we describe a zebrafish neuroblastoma yolk sac model to evaluate efficacy and toxicity of histone deacetylase (HDAC) inhibitor treatments. Larvae were engrafted with fluorescently labeled, genetically diverse, established cell lines and short-term cultures of patient-derived primary cells. Engrafted tumors progressed locally and disseminated remotely in an intact environment. Combination treatments involving the standard chemotherapy doxorubicin and HDAC inhibitors substantially reduced tumor volume, induced tumor cell death, and inhibited tumor cell dissemination to the tail region. Hence, this model allows for fast, cost-efficient, and reliable in vivo evaluation of toxicity and response of the primary and metastatic tumor sites to drug combinations.
Genes / Markers
Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping